For the Inventor, By the Inventor

Enter assignee name

Leiden, Netherlands

Biomarin Technologies B.v.

Calculating rank

USPTO Granted Patents = 16

CIPO Patents = 2

EPO Patents = 15

Forward Citations = 386

Loading Chart...

Loading Chart...

11 inventors (with patents filed for the assignee):

Judith Christina Theodora Van Deutekom (13 out of 23 patents)

Josephus Johannes De Kimpe (10 out of 15 patents)

Gerard Johannes Platenburg (9 out of 16 patents)

4. Garrit-Jan Boudewijn Van Ommen (6 out of 19 patents)

5. Annemieke Aartsma-Rus (4 out of 12 patents)

6. Peter Christian De Visser (3 out of 5 patents)

7. Derick Gert Wansink (2 out of 3 patents)

8. Adriana Marie Rus (2 out of 4 patents)

9. Susan Allegonda Maria Mulders (1 out of 2 patents)

10. Gerardus Johannes Platenburg (1 out of 8 patents)

11. Nicole Anne Datson (1 out of 1 patent)

12. Joseph Stephan Verbeek (1 patent)

13. Johannes Antonius Heemskerk (2 patents)

14. Petra Van Kuik-Romeijn (4 patents)

15. Judith Christina Van Deutekom (0 patent)

16 patents: Sort by Forward Citations

1. 12331293 - Bispecific antisense oligonucleotides for dystrophin exon skipping (2025-06-17),

2. 11427820 - Methods and means for efficient skipping of exon 45 in Duchenne muscular dystrophy pre-mRNA (2022-08-30),

3. 11034956 - Oligonucleotide comprising an inosine for treating DMD (2021-06-15),

4. RE48468 - Means and methods for counteracting muscle disorders (2021-03-15),

5. 10913946 - RNA modulating oligonucleotides with improved characteristics for the treatment of Duchenne and Becker muscular dystrophy (2021-02-09),

6. 10876114 - Methods and means for efficient skipping of at least one of the following exons of the human Duchenne muscular dystrophy gene: 43, 46, 50-53 (2020-12-29),

7. 10689646 - Treatment of genetic disorders associated with DNA repeat instability (2020-06-23),

8. 10533171 - Oligonucleotide comprising an inosine for treating DMD (2020-01-14),

9. 10246707 - Method for efficient exon (44) skipping in duchenne muscular dystrophy and associated means (2019-04-02),

10. 10179912 - RNA modulating oligonucleotides with improved characteristics for the treatment of duchenne and becker muscular dystrophy (2019-01-15),

11. 9926557 - Methods and means for efficient skipping of exon 45 in Duchenne muscular dystrophy pre-mRNA (2018-03-27),

12. 9890379 - Treatment of genetic disorders associated with DNA repeat instability (2018-02-13),

13. 9745576 - RNA modulating oligonucleotides with improved characteristics for the treatment of neuromuscular disorders (2017-08-29),

14. 9528109 - Methods and means for efficient skipping of exon 45 in duchenne muscular dystrophy pre-mRNA (2016-12-27),

15. 9499818 - Methods and means for efficient skipping of at least one of the exons 51-53, 55, 57 and 59 of the human duchenne muscular dystrophy gene (2016-11-22),

Company Overview

Biomarin Technologies B.V., based in Leiden, Netherlands, specializes in the development and manufacturing of innovative biopharmaceuticals. The company focuses on therapies for rare genetic disorders, leveraging advanced biotechnology to create effective treatments. With a commitment to improving patient outcomes, Biomarin engages in extensive research across various therapeutic areas, particularly in enzyme replacement therapies and gene therapies, aiming to address unmet medical needs globally.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Nov 3 2026

16 Patents

#13 in Leiden

#431 in Netherlands

#37,914 in the World

Leiden, Netherlands

Biomarin Technologies B.v.

Forward Citations = 386

11 inventors:

Judith Christina Theodora Van Deutekom (13 out of 23 patents)

Josephus Johannes De Kimpe (10 out of 15 patents)

Gerard Johannes Platenburg (9 out of 16 patents)

4. Garrit-Jan Boudewijn Van Ommen (6 out of 19 patents)

5. Annemieke Aartsma-Rus (4 out of 12 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Biomarin Technologies B.v.. Retrieved from https://idiyas.com/company/biomarin-technologies-b-v

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…